Britain's biggest drug maker GlaxoSmithKline is quite positive about its new drug that treats chronic form of asthma. Clinical trial results are strong enough to get them nod from the health regulators.

The company revealed that the drug mepolizumab was able to reduce asthma attacks by 50% and was quite effective in treating the problem among those, who took a long time to recover from asthma attack. Experts were of the view that there are high hopes that the drug would give another high to the success of the company in the market.

Officials were of the view that they are quite excited about the drug and already have pushed the drug into the final Phase III stage and would be able to present the drug by the end of 2012. The drug is injectable in nature and works by restricting the immune system chemical known as interleukin-5.

Lead researcher of the drug, Ian Pavord, from Leicester National Health Service Trust was of the view, "It seems to be a safe and effective treatment option for patients with eosinophilic asthma that is associated with frequent flare-ups, and may reduce the need for conventional treatment". The drug has already been tested on 621 patients.